PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent^®

Česká verzia

Authors: Richard Češka
Authors place of work: Centrum preventivní kardiologie III. interní kliniky 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2015; 61(11): 946-951
Category: Reviews

Summary

At the present time there are novel hypolipidemics registered globally (alirocumab was the first drug of this group in the world registered by an American drug agency FDA) and in Europe, which in many ways differ from the medicines administered until now. They are bringing another advancement in the treatment of disorders of lipid metabolism and in preventive cardiology. Alirocumab is a fully human monoclonal antibody to PCSK-9 enzyme (proprotein convertase subtilisin kexin-9). PCSK-9 enzyme plays an important role in the metabolism of LDL-cholesterol through affecting the breakdown and eventually the amount and activity of LDL-receptors. From the clinical point of view it is essential that drugs from this group are administered parenterally, as a subcutaneous injection. In the case of Praluent^® the interval between administration is two weeks. The dose is then 75 or 150mg in a 1ml injection. From the clinical point of view it is particularly important that alirocumab decreases LDL-C concentrations by 50–60%, it decreases Lp/a/ levels by 25–30%, and it also positively influences other components of lipid metabolism and, above all, is very likely to have a potential to decrease a cardiovascular risk. Although the resuIts of morbidity and mortality studies are expected in the coming years, initial analyses strongly indicate a clinically significant reduction of CV events. Alirocumab, Praluent can be administered as monotherapy (mainly to statin-intolerant patients), however it will be primarily administered in combination with the other hypolipidemic drugs (in particular statins) where the effort to reach target values has not succeeded.

Key words:
alirocumab – familial hypercholesterolemia – hypercholesterolemia – hypolipidemics – Praluent^®

Zdroje

1. Watts GF, Gidding S, Wierzbicki AS et al. Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171 (3): 309–325.

2. Reiner Z, Catapano AL, De BG et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769–1818.

3. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670–1681.

4. Mihaylova B, Emberson J, Blackwell L et al. Cholesterol Treatment Trialists‘ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581–590.

5. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574.

6. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.Eur Heart J 2013; 34(45): 3478–3490.

7. Robinson JG, Farnier M, Krempf M. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015; 372(16): 1489–1499.

8. Moriarty PM, Jacobson TA, Bruckert E et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014; 8(6): 554–561.

9. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397.

10. McKenney J, Swergold G, DiCioccio T et al. Dynamics between the monoclonal antibody sar236553/regn727, proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein cholesterol (LDL-C) Levels (Funding: Regeneron/Sano) [abstract no. 298]. In: European Atherosclerosis Society Annual Congress 2013.

11. Lunven C, Paehler T, Poitiers F et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther 2014; 32(6): 297–301.

12. Regeneron Pharmaceuticals Inc, Sano-aventis. PRALUENT (alirocumab): US prescribing Information 2015. Dostupné z WWW: <http://www.regeneron.com/Praluent/Praluent-fpi>.

13. Rey J, Poitiers F, Paehler T et al. Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, administered every 4 weeks alone or in combination with ezetimibe or fenobrate in healthy subjects [abstract no. 1183–131]. J Am Coll Cardiol 2014; 63(12 Supplement): A1375.

14. Kereiakes DJ, Robinson JG, Cannon CP et al. Efcacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 2015; 169(6): 906–915.

15. Cannon CP, Cariou B, Blom D et al. Efcacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015; 36}19]: 1186–1194.

16. Robinson JG, Farnier M, Krempf M et al. Efcacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1489–1499.

17. Bays H, Gaudet D, Weiss R et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 2015; 100(8): 3140–3148.

18. Bays H, Farnier M, Gaudet D et al. Efcacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensication or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II [abstract]. Circulation 2015; 130(23): 2118–2119.

19. Roth E, Rader DJ, Moriarty P. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [abstract no. 0254]. In: 17th International Symposium on Atherosclerosis. 2015.

20. McKenney JM, Koren MJ, Kereiakes DJ et al. Safety and efcacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59(25): 2344–2353.

21. Roth EM, McKenney JM, Hanotin C et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367(20): 1891–1900.

22. Teramoto T, Kobayashi M, Uno K et al. Efcacy and safety of alirocumab in Japanese patients with hypercholesterolemia on stable statin therapy: rst data with the 75 mg every two weeks dose [abstract no. 13651]. In: 87th Annual Scientic Sessions of the American Heart Association 2014.

23. Roth EM, Taskinen MR, Ginsberg HN et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol 2014; 176(1): 55–61.

24. Moriarty PM, Thompson PD, Cannon CP et al. ODYSSEY ALTERNATIVE: efcacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as dened by a placebo run-in and statin rechallenge arm. Circulation 2014; 130(23): 2108–2109.

25. Stroes E, Guyton J, Farnier M. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [abstract no. 0269]. In: 17th International Symposium on Atherosclerosis 2015.

26. Kastelein JJ, Robinson JG, Farnier M. Efcacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies [abstract no. 2125]. In: European Society of Cardiology 2015.

27. Ginsberg HN, Rader DJ, Raal FJ. ODYSSEY HIGH FH: efcacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation 2014; 130(23): 2119.

28. Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380(9836): 29–36.